Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

36.20 +0.59 (+1.66%)
Streaming Delayed Price Updated: 11:05 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis Inc

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Exelixis Stock Sees Rising Relative Strength Rating
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before. 
Via Investor's Business Daily
3 Biotech Stocks You’ll Regret Not Buying Soon
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
Analyst Expectations for Exelixis's Future
Via Benzinga
Exelixis (EXEL) Q2 2023 Earnings Call Transcript
EXEL earnings call for the period ending June 30, 2023. 
Via The Motley Fool
2 Biotech Growth Stocks I'd Buy Right Now
Both drugmakers seem to have a bright future ahead. 
Via The Motley Fool
8 Analysts Have This to Say About Exelixis
Via Benzinga
Exelixis (EXEL) Q1 2023 Earnings Call Transcript
EXEL earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil
There is opportunity in a crisis. Key biotech stocks amid turmoil could be the greatest deals on the market today. 
Via InvestorPlace
7 Best Cancer Stocks to Invest in Now
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now. 
Via MarketBeat
Topics Death
Exposures Death
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
From Exelixis, Inc.
Via Business Wire
Exelixis: Q1 Earnings Insights
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector. 
Via InvestorPlace
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
From Exelixis, Inc.
Via Business Wire
3 No-Brainer Stocks to Buy With $200 Right Now
A modest amount of money can go a long way when it's invested in game-changing businesses. 
Via The Motley Fool
Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board
From Farallon Capital Management L.L.C.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
These companies can take investors on a lucrative ride, and all for the price of a few lattes. 
Via The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
Companies that don't make a lot of noise can still make you a lot of money. 
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines. 
Via The Motley Fool
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
Nasdaq Bear Market: 5 Exceptional Growth Stocks You'll Regret Not Buying on the Dip
A sizable dip in the innovation-driven Nasdaq Composite is the perfect excuse for investors to pounce on some phenomenal deals. 
Via The Motley Fool
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Amid Proxy Challenge From Farallon, Exelixis' Board Member Resigns
Exelixis Inc's (NASDAQ: EXEL) board member Lance Willsey announced his resignation from the Board,  
Via Benzinga
Farallon Capital Management Comments on Successful Campaign for Change at Exelixis
From Farallon Capital Management L.L.C.
Via Business Wire
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
From Exelixis, Inc.
Via Business Wire
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
From Exelixis, Inc.
Via Business Wire
Farallon Capital Urges Exelixis Shareholders to Support Change by Electing Its Three Highly Qualified Director Candidates
From Farallon Capital Management L.L.C.
Via Business Wire
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.